At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 332 enrolled
Drug / intervention
CNTX-4975-05 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection of CNTX-4975-05 in Subjects With Chronic, Moderate-to-severe Osteoarthritis Knee Pain
In Brief
A Phase 3 clinical trial evaluating CNTX-4975-05 and Placebo for Osteoarthritis, Knee. Completed, enrolled 332 participants across 33 sites.
Detailed Summary
This is a phase 3, randomized, double-blind, placebo-controlled, single injection, 52-week study to evaluate the analgesic efficacy and safety of a single intra-articular (IA) CNTX-4975-05 (capsaicin), compared to IA placebo, in subjects with chronic, moderate-to-severe osteoarthritis (OA) knee pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedFeb 2018
Primary CompletionNov 2019
TodayJul 2026
First PostedFeb 12, 2018
Enrollment StartJan 24, 2018
Primary CompletionNov 22, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.4 years ago
Interventions
CNTX-4975-05drug
Receiving CNTX-4975-05 injection
Placebodrug
Receiving Placebo injection